Phase II Study of Tirelizumab Combined With Cetuximab and Irinotecan in the Treatment of Recurrent, Refractory mCRC
Status:
Recruiting
Trial end date:
2024-02-28
Target enrollment:
Participant gender:
Summary
This is a single arm, open phase II study to evaluate the efficacy and safety of tirelizumab
combined with cetuximab + irinotecan in the treatment of Ras wild-type recurrent and
refractory colorectal cancer. This study will include Ras wild-type colorectal cancer that
failed at least second-line treatment in the past, including chemotherapy (oxaliplatin,
irinotecan, fluorouracil) with or without targeted drugs (cetuximab, bevacizumab). 33
patients were planned to be treated with tirelizumab combined with cetuximab + irinotecan
every 2 weeks. The enrollment time is expected to be 12 months and the follow-up is 24
months.